Characterization of a Protein Kinase that Phosphorylates Serine 189 of the Mitogen-activated Protein Kinase Homolog ERK3 (*)

  1. Melanie H. Cobb(¶),
  1. From the University of Texas Southwestern Medical Center, Departments of Pharmacology and
  2. Biochemistry, Dallas, Texas 75235-9041
  1. To whom correspondence should be addressed: The University of Texas Southwestern Medical Center, Dept. of Pharmacology, 5323 Harry Hines Blvd., Dallas, TX 75235-9041. Tel.: 214-648-3627; Fax: 214-648-2971.

Abstract

A novel protein kinase activity present in nuclear and cytosolic extracts has been identified and partially purified as a consequence of its tight binding to and phosphorylation of the extracellular signal-regulated protein kinase (ERK) 3. This novel protein kinase is inactivated by treatment with phosphoprotein phosphatase 2A. The ERK3 protein kinase was immunologically distinct from mitogen-activated protein (MAP) kinase/ERK kinases (MEK) 1 and 2 which phosphorylate the ERK3-related MAP kinases ERK1 and ERK2. This ERK3 kinase phosphorylated a single site on ERK3, SerGraphic, comparable to ThrGraphic, one of the two activating phosphorylation sites of ERK2. To test the specificity of the ERK3 kinase, mutants of ERK3 and ERK2 were made in which the phosphorylated residues were exchanged. The double mutant S189T,G191Y ERK3, in which the phosphorylated residues from ERK2 replaced the comparable residues in ERK3, was phosphorylated by the ERK3 kinase but only on threonine. The ERK3 kinase did not phosphorylate ERK2 or ERK2 mutants. These findings indicate that although the ERK3 kinase is highly specific for ERK3, it does not recognize tyrosine, a feature that distinguishes it from MEKs that phosphorylate other ERK/MAP kinase family members.

Footnotes

  • § In partial fulfillment of the requirements for the Ph.D. degree.

  • * This work was supported in part by research grants from the Welch Foundation (I-1243), Texas Advanced Research Program, National Institutes of Health (DK34128), and the Council for Tobacco Research, a predoctoral fellowship (to D. E.) from Merck Research Laboratories Academic Development Program, and a postdoctoral fellowship (to M. J. R.) from the Arthritis Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Received January 25, 1996.
  • Revision received March 4, 1996.
Table of Contents

Submit your work to JBC.

You'll be in good company.